NDC product
Zegalogue
NDC 0169-1913 · Novo Nordisk
Key facts
| Product NDC | 0169-1913 |
|---|---|
| Proprietary name | Zegalogue |
| Nonproprietary name | dasiglucagon |
| Substances | DASIGLUCAGON |
| Dosage form | INJECTION, SOLUTION |
| Route | SUBCUTANEOUS |
| Labeler | Novo Nordisk |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA214231 |
| Pharmacologic classes | Antihypoglycemic Agent [EPC], Glucagon Receptor Agonists [MoA], Increased Glycogenolysis [PE] |
| Marketing start | Jun 26, 2023 |
| Marketing end | Aug 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory